TherapeuticsMD Inc (NASDAQ:TXMD) Receives $9.71 Average Target Price from Brokerages

Share on StockTwits

Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have been assigned an average rating of “Buy” from the ten analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.57.

Several equities research analysts have commented on the stock. Noble Financial restated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research note on Monday, August 12th. JPMorgan Chase & Co. decreased their price objective on shares of TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, June 11th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Saturday, August 10th. Jefferies Financial Group decreased their price objective on shares of TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating for the company in a report on Monday, July 15th. Finally, Oppenheimer set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 22nd.

Shares of NASDAQ:TXMD opened at $2.64 on Friday. The firm’s 50 day moving average is $2.50 and its two-hundred day moving average is $3.76. TherapeuticsMD has a 52 week low of $1.82 and a 52 week high of $6.94. The firm has a market capitalization of $658.54 million, a P/E ratio of -4.47 and a beta of 1.90. The company has a current ratio of 5.17, a quick ratio of 4.99 and a debt-to-equity ratio of 24.29.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The firm had revenue of $6.08 million during the quarter, compared to analyst estimates of $5.12 million. During the same quarter in the previous year, the business posted ($0.15) EPS. TherapeuticsMD’s revenue for the quarter was up 60.0% compared to the same quarter last year. Analysts predict that TherapeuticsMD will post -0.73 EPS for the current year.

In other TherapeuticsMD news, insider John C.K. Iv Milligan bought 15,000 shares of TherapeuticsMD stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $3.16 per share, for a total transaction of $47,400.00. Following the completion of the acquisition, the insider now owns 1,472,419 shares of the company’s stock, valued at approximately $4,652,844.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Angus C. Russell bought 35,000 shares of TherapeuticsMD stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average price of $2.83 per share, with a total value of $99,050.00. Following the completion of the acquisition, the director now directly owns 73,500 shares of the company’s stock, valued at approximately $208,005. The disclosure for this purchase can be found here. Insiders bought 170,549 shares of company stock valued at $493,167 over the last quarter. Insiders own 18.91% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. boosted its holdings in TherapeuticsMD by 45.5% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 24,973 shares of the company’s stock worth $65,000 after buying an additional 7,810 shares in the last quarter. Bamco Inc. NY boosted its holdings in TherapeuticsMD by 41.8% during the second quarter. Bamco Inc. NY now owns 3,331,500 shares of the company’s stock worth $8,662,000 after buying an additional 981,500 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in TherapeuticsMD during the second quarter worth approximately $2,218,000. UBS Asset Management Americas Inc. boosted its holdings in TherapeuticsMD by 19.6% during the second quarter. UBS Asset Management Americas Inc. now owns 143,932 shares of the company’s stock worth $374,000 after buying an additional 23,539 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in TherapeuticsMD by 100.0% during the second quarter. Jane Street Group LLC now owns 120,607 shares of the company’s stock worth $314,000 after buying an additional 60,296 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: Different Types of Derivatives

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vanguard Small-Cap Value ETF  Stock Position Lessened by Zhang Financial LLC
Vanguard Small-Cap Value ETF Stock Position Lessened by Zhang Financial LLC
Zhang Financial LLC Sells 466 Shares of iShares Select Dividend ETF
Zhang Financial LLC Sells 466 Shares of iShares Select Dividend ETF
Pettinga Financial Advisors LLC Buys 865 Shares of iShares Global Tech ETF
Pettinga Financial Advisors LLC Buys 865 Shares of iShares Global Tech ETF
Intec Pharma  Rating Increased to Buy at Zacks Investment Research
Intec Pharma Rating Increased to Buy at Zacks Investment Research
Palomar  Rating Lowered to Hold at Zacks Investment Research
Palomar Rating Lowered to Hold at Zacks Investment Research
UBS Group Initiates Coverage on Akazoo
UBS Group Initiates Coverage on Akazoo


© 2006-2019 Ticker Report